Huntsman Cancer Institute Hari Lab

Publications

View all Vankayalapati H publications in the NIH PubMed Database

Selected Publications:

Development of high-​throughput screening assays for inhibitors of ETS transcription factors.
Currie, SL.; Warner, SL.; Vankayalapati, H, Liu, X, Sharma, S, Bearss, DJ, Graves, BJ.
SLAS Discov. 2019, 1, 77-85. PMID: 30204534


Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors.
Chen T, Sorna V, Choi S, Call L, Bearss J, Carpenter K, Warner SL, Sharma S, Bearss, DJ, Vankayalapati, H
Bioorg Med Chem Lett. 2017, 27 (24) 5473-5480. PMID: 29150397


Repurposing of Proton Pump Inhibitors as First Identified Small Molecule Inhibitors of Endo-β-N-acetylglucosaminidase (ENGase) for the Treatment of Rare NGLY1 Genetic Disease.
Bi Y, Might M, Vankayalapati H, Kuberan B.
Bioorg Med Chem Lett. 2017, 27(13), 2962-2966. PMID: 28512024


Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime beta-Catenin Pathway Inhibitors.
Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, Sharma.
J Med Chem, 2015, 58(15), 5854-62. PMID: 26182238


Inhibition of Nek2 by small molecules affects proteasome activity.
Meng L, Carpenter K, Mollard A, Vankayalapati H, Warner SL, Sharma S, Tricot G, Zhan F, Bearss DJ.
Biomed Res Int, 2014, 273180. PMID: 25313354


High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors.
Sorna V, Theisen ER, Stephens B, Warner SL, Bearss DJ, Vankayalapati H, Sharma S.
J Med Chem, 2013, 56(23), 9496-508. PMID: 24237195


Discovery of Novel Putative Inhibitors of UDP-GlcNAc 2-Epimerase as Potent Antibacterial Agents.
Xu Y, Brenning B, Clifford A, Vollmer D, Bearss J, Jones C, McCarthy V, Shi C, Wolfe B, Aavula B, Warner S, Bearss DJ, McCullar MV, Schuch R, Pelzek A, Bhaskaran SS, Stebbins CE, Goldberg AR, Fischetti VA, Vankayalapati H.
ACS Med Chem Lett, 2013, 4 (12), 1142-1147. PMID: 24443700


A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma.Lorenzo FR, Yang C, Ng Tang Fui M, Vankayalapati H, Zhuang Z, Huynh T, Grossmann M, Pacak K, Prchal JT.
J Mol Med (Berl), 2013, 91 (4), 507-12. PMID: 23090011


Chemical genetic screen reveals a role for desmosomal adhesion in mammary branching morphogenesis.
Basham KJ, Kieffer C, Shelton DN, Leonard CJ, Bhonde VR, Vankayalapati H, Milash B, Bearss DJ, Looper RE, Welm BE.
J Biol Chem, 2013, 288 (4), 2261-70. PMID: 23212921


Use of a bacteriophage lysin to identify a novel target for antimicrobial development.
Schuch R, Pelzek AJ, Raz A, Euler CW, Ryan PA, Winer BY, Farnsworth A, Bhaskaran SS, Stebbins CE, Xu Y, Clifford A, Bearss DJ, Vankayalapati H, Goldberg AR, Fischetti VA (2013).
PLoS One, 8(4), e60754. PMID: 23593301


Molecular heterogeneity of glucose-6-phosphate dehydrogenase deficiency in Gaza Strip Palestinians.
Sirdah M, Reading NS, Vankayalapati H, Perkins SL, Shubair ME, Aboud L, Roper D, Prchal JT.
Blood Cells Mol Dis, 2013, 49 (3-4), 152-8. PMID: 22770933


Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer.
Lanikova L, Lorenzo F, Yang C, Vankayalapati H, Drachtman R, Divoky V, Prchal JT.
Blood, 2013, 121 (19), 3918-24. PMID: 23538339


Innovative therapy for Classic Galactosemia - Tale of two HTS.
Tang, M, Odejinmi, SI, Vankayalapati, H, Wierenga, KJ, Lai, K.
Mol Genet Metab, 2012, 105 (1), 44-55. PMID: 22018723


Identification of novel small molecule inhibitors of 4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) kinase of Gram-negative bacteria.
Tang M, Odejinmi SI, Allette YM, Vankayalapati H, Lai K.
Bioorg Med Chem, 2011, 19 (19), 5886-5895. PMID: 21903402


Targeting Axl and Mer kinases in cancer. [Review].
Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S.
Mol Cancer Ther, 2011, 10 (10), 1763-73. PMID: 21933973


Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.
Mollard A, Warner SL, Call LT, Wade ML, Bearss JJ, Verma A, Sharma S, Vankayalapati H, Bearss DJ.
ACS Med Chem Lett, 2011, 2 (12), 907-912. PMID: 22247788.


Structure-activity analysis and cell-based optimization of human galactokinase inhibitors.Odejinmi S, Rascon R, Tang M, Vankayalapati H, Lai K (2011).
ACS Med Chem Lett, 2(9), 667-672. PMID: 22125663